PortfoliosStock ScreensStocksStockXcel

QNCX

QNCX | US

0.18

USD

0.02

12.33%

QNCX | US

About QNCX

Sector

Healthcare

Industry

Biotechnology

Earnings date

30/06/2024

As of date

08/04/2026

Close

0.18

Open

0.33

High

0.38

Low

0.17

Quince Therapeutics Inc. a preclinical stage biopharmaceutical company develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004 a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme Inc. and changed its name to Quince Therapeutics Inc. in August 2022. Quince Therapeutics Inc. was incorporated in 2012 and is headquartered in South San Francisco California.

View Less

QNCX | US

Risk
326.1
Sharpe
-0.25
Luna's Score
51/100
Recommendation
Hold

Luna says (QNCX | US)

What's Working

Strength based on increasing price with high volume

High Current Volume and Positive 1-Day Return

Low Debt to Asset (< 0.2)

Value Stock (Price to Book < 3)

What's not Working

High 6-Month Volatility (>65%)

Microcap (<300M USD)

High Market Beta (> 0.8)

Weak Sharpe Ratio (< 0.3)

Volatility Signals

Bearish: Increased Volatility (6-month > 1-month volatility)

Risk Meter

10 days

451.4%

1 month

326.1%

3 months

696.1%

6 months

497.7%

Returns

Fundamental Ratios

PE

-

Fwd. PE

-

Price to book

0.73

Debt to equity

0.31

Debt to assets

0.11

Ent. to EBITDA

1.44

Ent. to rev.

-

PEG

-

Other Fundamentals

EBITDA

-29.13M

MarketCap

7.92M

MarketCap(USD)

7.92M

Div. yield

-

Op. margin

-

Erngs. growth

-

Rev. growth

-

Ret. on equity

-79.38

Short ratio

20.83

Short perc.

4.80

Market Sentiment (SMA and Price signals)

Short-term: Bullish (SMA10D > SMA1M)

Intermediate-term: Bearish (SMA1M < SMA3M)

Long-term: Bullish (SMA6M > SMA12M)

SMAs: Stock Price Trends

Range10D

0.30

Range1M

0.30

Range3M

3.64

Volumes: Market Activity

Rel. volume

11.29

Price X volume

208.42M

Peers

Name
Ticker
Industry
Close
Marketcap
Day Return
PE Ratio
Debt to Equity
 
 
 
 
 
 
 
 
InMed Pharmaceuticals IncINMBiotechnology0.64678.63M-4.95%n/a7.00%
NovaBay Pharmaceuticals IncNBYBiotechnology1.748.50M2.35%n/a-325.77%
KPRXKPRXBiotechnology2.868.50M32.41%0.210.25%
XORTX Therapeutics Inc. Common StockXRTXBiotechnology2.818.46M30.70%n/a3.09%
Cyclerion Therapeutics IncCYCNBiotechnology2.897.27M-16.95%n/a0.00%
Common StockADXNBiotechnology6.486.93M6.23%n/a0.25%
Moleculin Biotech IncMBRXBiotechnology2.436.91M0.83%n/a3.00%
Ensysce Biosciences IncENSCBiotechnology0.4956.87M-14.08%n/a24.79%
CALCCALCBiotechnology0.6236.70M-2.81%n/a0.00%
Purple Biotech LtdPPBTBiotechnology4.236.66M2.42%n/a0.89%
  • 1

Diversifiers

Name
Ticker
Industry
Close
Marketcap
Day Return
PE Ratio
Debt to Equity
 
 
 
 
 
 
 
 
Beasley Broadcast Group IncBBGIBroadcasting - Radio5.678.64M80.57%n/a204.46%
EZGO Technologies Ltd. Ordinary SharesEZGORecreational Vehicles1.2643.23M2.35%n/a17.32%
Twin Vee PowerCats Co. Common StockVEEERecreational Vehicles0.26922.56M21.37%n/a19.98%
Vision Marine Technologies IncVMARRecreational Vehicles2.021.11M-0.98%n/a0.00%
  • 1

Industry Comparison

ParameterCompanyIndustryIndicator
Enterprise to EBITDA1.44-Expensive
Ent. to Revenue---
PE Ratio-41.03-
Price to Book0.7315.55Cheaper
Dividend Yield---
Std. Deviation (3M)696.09-Riskier
Debt to Equity0.31-1.23Expensive
Debt to Assets0.110.25Cheaper
Market Cap7.92M-Emerging
  • 1

Unlock Your Investing Potential

Register with Xstocks

Join over 2,000+ Investors

Register now and embark on your journey to informed and successful investing.

Explore Industry Correlations

Explore Industry Correlations

Uncover Trading and Hedging Opportunities

Gain valuable insights into potential trading opportunities and discover strategic hedging possibilities

Discover Top-Performing Industries

Discover Top performing Industries

Explore Stocks for Short and Long-Term Gains

Uncover opportunities at both short-term and long-term horizons, allowing you to make informed investment decisions.

Follow us @XStocks007